Rat Model Market Report 2025

The rat model market size has grown strongly in recent years. It will grow from $1.65 billion in 2024 to $1.77 billion in 2025 at a compound annual growth rate (CAGR) of 7.4%. The growth in the historic period can be attributed to rising demand for preclinical research, increasing government funding, research demand, drug development initiatives, and rising chronic disease.

The rat model market size is expected to see strong growth in the next few years. It will grow to $2.56 billion in 2029 at a compound annual growth rate (CAGR) of 9.8%. The growth in the forecast period can be attributed to expanding applications in personalized medicine, growing demand for animal models in drug discovery, increasing focus on disease prevention, expansion of the biopharmaceutical industry, innovation in imaging techniques, and government and private funding. Major trends in the forecast period include global collaborations in research, technological advancements in imaging, integration of omics technologies, advancements in genome editing techniques, the growing importance of rat models in disease research, and the rise of personalized medicine and customized rat models.

The increasing prevalence of chronic diseases is expected to drive growth in the rat model market in the future. Chronic diseases are conditions that last for a year or more, interfere with daily activities, require ongoing medical care, or a combination of these factors. Rat models have been crucial in studying the pathogenesis, immune responses, and treatments for chronic infections, offering valuable insights that aid in the development of new therapies and interventions. For example, in September 2023, the World Health Organization, a specialized agency of the United Nations based in Switzerland, reported that there are 41 million deaths annually, accounting for 74% of deaths caused by non-communicable diseases (NCDs) or chronic diseases worldwide. Thus, the rising incidence of chronic diseases is fueling the growth of the rat model market.

The growing demand for medicines is expected to drive the rat model market's growth in the near future. Rat models facilitate research on various medications, as they are easier to feed and smaller than more complex mammals like primates, making them a more convenient option. Consequently, the increase in medicine demand boosts the need for rat models. For instance, in July 2024, the National Center for Biotechnology Information, a US-based government agency, reported that total medicine spending in the United States rose by 13.6% in 2023 compared to 2022, reaching $722.5 billion. Therefore, the rising demand for medicines is propelling the growth of the rat model market.

Major players in the rat model market are actively pursuing strategic partnerships for preclinical research, particularly in areas such as oncology and other therapeutic domains. By collaborating with companies specializing in rat models, these firms can focus on their core business activities while benefiting from the expertise, efficiency, and cost-effectiveness of these specialized providers, which possess established infrastructure and resources for generating rat models. One notable example is the partnership between Hera BioLabs, a US-based biotechnology company, and Charles River Laboratories, International Inc., a US-based pharmaceutical company. In March 2022, they joined forces for the commercialization of Hera's SRG rat, also known as OncoRat. Under this collaboration, Charles River will handle the breeding, distribution, sale, and marketing of the SRG rat directly to the preclinical research community. The SRG rat, characterized as a highly immunodeficient rat, is well-suited for xenograft or PDX studies, offering distinct advantages over mouse models for in vivo efficacy evaluation of potential cancer therapies. This model addresses limitations seen in smaller mouse models, allowing for larger tumor growth, simplified surgeries, and increased tissues and serum for analyses, including repeat sampling.

Major companies in the rat model market are concentrating on creating innovative solutions, such as super immunodeficient mouse models, to improve research outcomes. Super immunodeficient mouse models are genetically modified mice with severely compromised immune systems, making them essential for various biomedical research applications. For example, in October 2022, Taconic Biosciences, a US-based biotechnology company, introduced the FcResolv NOG portfolio, which includes the first and only super immunodeficient mouse models that lack residual murine Fc gamma receptors (FcγRs). This pioneering development enhances the evaluation of antibody therapies by providing a more precise preclinical platform, reducing interference from murine FcγRs. Built on the CIEA NOG mouse, these models facilitate studies of the human immune system and can be customized to meet specific research needs, ultimately advancing the field of immunotherapy research and development.

In November 2023, Scantox A/S, a Denmark-based company focused on preclinical pharmacology, acquired QPS Austria GmbH for an undisclosed sum. This acquisition is intended to strengthen Scantox A/S's capabilities in drug discovery, particularly in the fields of neurodegenerative diseases, rare diseases, and mental disorders. QPS Austria GmbH, based in Austria, specializes in contract research services for rat models.

Major companies operating in the rat model market include Genoway S.A., Biomere, Transposagen Biopharmaceuticals Inc., Horizon Discovery Group PLC, Transviragen Inc., Charles River Laboratories International Inc., Taconic Biosciences Inc., Envigo Ltd., Laboratory Corporation of America Holdings, Janvier Labs, Harlan Laboratories Inc., Sage Path Labs, Applied StemCell Inc., Regenera Pharma Ltd., Cyagen Biosciences Inc., Ozgene Pty Ltd, Yecuris Corporation, Hera BioLabs Inc., Beijing Biocytogen Co. Ltd., Ingenious Targeting Laboratory, InVivos Pte Ltd., Kymab Limited, Mirimus Inc., Pharmaron Beijing Co. Ltd., PolyGene AG, Shanghai Model Organisms Center Inc., Sino Biological Inc., Synthego Corporation, Transgenic Inc., ViGene Biosciences Inc., Viva Biotech Holdings, WuXi AppTec Co. Ltd.

North America was the largest region in the rat model market in 2024. Asia-Pacific is expected to be the fastest-growing region in the global rat model market report during the forecast period. The regions covered in the rat model market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the rat model market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The utilization of rat models involves leveraging rat functional genes, cells, tissues, and organs to simulate both healthy and pathological conditions of the human immune system. Humanized rat models play a crucial role in preclinical research, offering a means to replicate human disease states, assess the efficacy of compounds, and analyze their impact on human proteins.

Various types of rat models are available, including knockout, outbred, inbred, hybrid, immunodeficient, and conditioned models. In the context of knockout models, scientists modify or replace a gene to deactivate it, providing a valuable tool for studying the effects of specific gene alterations. Services provided encompass cryopreservation, breeding, re-derivation, genetic testing, and quarantine, utilizing technologies such as nuclear transferase, microinjection, and embryonic stem cells. These services cater to a range of applications, including oncology, neurology, immunology, toxicology, and more.

The rat models market research report is one of a series of new reports that provides rat models market statistics, including the rat models industry's global market size, regional shares, competitors with a rat models market share, detailed rat models market segments, market trends, and opportunities, and any further data you may need to thrive in the rat models industry. This rat models market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The rat model market includes revenues earned by entities by providing services such as DNA preparation, genotyping services, knock-in, or transgenic rat or mouse model creation. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.